National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2018.
Walker TY, Elam-Evans LD, Yankey D, Markowitz LE, Williams CL, Fredua B, Singleton JA, Stokley S. · 2019
Read National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2018. by Walker TY, Elam-Evans LD, Yankey D, Markowitz LE, Williams CL, Fredua B, Singleton JA, Stokley S. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6705894.txt.
Introduction
Walker and co-authors report teen vaccination rates in the United States for 2018. Their report appeared in the Morbidity and Mortality Weekly Report. It draws on a national survey of teens aged 13 to 17. The shots covered include those against HPV, meningococcal disease, and whooping cough.
The survey covered 18,700 teens in all parts of the country. Coverage with at least one HPV dose rose from 65.5 percent in 2017 to 68.1 percent a year later. The share fully up to date on HPV rose from 48.6 percent at the start to 51.1 percent by the end. Tdap coverage held steady at 89 percent that year. Gaps by city type and insurance status stayed in place.
Catalog record
| CREATOR | Walker TY, Elam-Evans LD, Yankey D, Markowitz LE, Williams CL, Fredua B, Singleton JA, Stokley S. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2018 By Tanja Y Walker, Laurie D Elam-Evans, David Yankey, Lauri E Markowitz, Charnetta L Williams, Benjamin Fredua, James A Singleton, Shannon Stokley Published in: Morbidity and Mortality Weekly Report DOI: 10.15585/mmwr.mm6833a2 The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of persons aged 11–12 years to protect against certain diseases, including human papillomavirus (HPV)–associated cancers, meningococcal disease, and pertussis (1). A booster dose of quadrivalent meningococcal conjugate vaccine (MenACWY) is recommended at age 16 years, and serogroup B meningococcal vaccine (MenB) may be administered to persons aged 16–23 years (1). To estimate vaccination coverage among adolescents in the United States, CDC analyzed data from the 2018 National Immunization Survey–Teen (NIS-Teen) which included 18,700 adolescents aged 13–17 years.* During 2017–2018, coverage with ≥1 dose of HPV vaccine increased from 65.5% to 68.1%, and the percentage of adolescents up-to-date† with the HPV vaccine series increased from 48.6% to 51.1%, although the increases were only observed among males. Vaccination coverage increases were also observed for ≥1 MenACWY dose (from 85.1% to 86.6%) and ≥2 MenACWY doses (from 44.3% to 50.8%). Coverage with tetanus and reduced diphtheria toxoids and acellular pertussis vaccine (Tdap) remained stable at 89%. Disparities in coverage by metropolitan statistical area (MSA)§ and health insurance status identified in previous years persisted (2). Coverage with ≥1 dose of HPV vaccine was higher among adolescents whose parents reported receiving a provider recommendation; however, prevalence of parents reporting receiving a recommendation for adolescent HPV vaccination varied by state (range = 60%–91%). Supporting providers to give strong recommendations and effectively address parental concerns remains a priority, especially in states and rural areas where provider recommendations were less commonly reported. NIS-Teen is an annual survey that monitors vaccines received by adolescents aged 13–17 years in the 50 states, the District of Columbia, selected local areas, and U.S. territories.¶ NIS-Teen is conducted among parents and guardians of eligible adolescents identified using a random-digit–dialed sample of cell phone numbers.** During the telephone interview, information is obtained on the sociodemographic characteristics of the teen and household, and contact information and consent to contact the teen’s vaccination providers are requested. Vaccination providers identified during the interview are mailed a questionnaire requesting the vaccination history from the teen’s medical record.†† Vaccination coverage estimates are based on provider-reported vaccination histories. This report presents vaccination coverage estimates for 18,700 adolescents (8,928 [48%] females and 9,772 [52%] males) aged 13–17 years with adequate provider data.§§ The overall Council of American Survey Research Organizations response rate was 23.3%, and only 48.3% of adolescents with completed interviews had adequate provider data. Previously described NIS-Teen methodology, including methods for weighting and synthesizing provider-reported vaccination histories (https://www.cdc.gov/vaccines/imz-managers/nis/downloads/NIS-TEEN-PUF17-DUG.pdf) was used. Beginning in 2018, NIS-Teen used a single-frame sample of cell phone lines. The landline telephone–sample frame that was used from 2006 through 2017 was dropped because of the declining number of landline-only households in the United States (https://www.cdc.gov/vaccines/imz-managers/coverage/teenvaxview/pubs-presentations/dual-to-single-frame-teen.html). Data were weighted and analyzed to account for the complex sampling design. T-tests were used to assess vaccination coverage differences by survey year (2018 compared with 2017) and between demographic subgroups. P-values <0.05 were considered statistically significant. SAS-callable SUDAAN (version 11; SAS Institute) was used to conduct all analyses. NATIONAL VACCINATION COVERAGE In 2018, 51.1% of adolescents aged 13–17 years were up to date with the HPV vaccine series, and 68.1% had received ≥1 dose of HPV vaccine (Table 1) (Figure). During 2017–2018, the increase in HPV vaccination coverage was attributable to increases among males only (increase of 4.4 percentage points in males who were up to date versus 0.6 in females). Coverage with ≥1 MenACWY dose increased by 1.5 percentage points to 86.6%. Among persons aged 17 years, coverage with ≥2 MenACWY doses increased by 6.5 percentage points to 50.8%. Coverage with ≥1 dose of MenB among persons aged 17 years was 17.2% (95% confidence interval = 14.9%–19.9%). No significant increases were observed for coverage with ≥3 hepatitis B doses; ≥2 measles, mumps, and rubella vaccine doses; and ≥1 and ≥2 varicella vaccine doses among adolescents without a history of varicella disease (Table 1). [Table: Estimated coverage with selected vaccines and doses among adolescents aged 13–17* years, by age at interview — National Immunization Survey–Teen (NIS-Teen), United States, 2018] [Figure: Estimated vaccination coverage with selected vaccines and doses* among adolescents aged 13–17 years, by survey year and Advisory Committee on Immunization Practices (ACIP) recommendations† — National Immunization Survey–Teen (NIS-Teen),§,¶ United States, 2006–2018Abbreviations: HPV = human papillomavirus vaccine; MenACWY = quadrivalent meningococcal conjugate vaccine; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; UTD = up-to-date.* ≥1 dose Tdap at or after age 10 years; ≥1 dose MenACWY or meningococcal-unknown type vaccine; ≥2 doses MenACWY or meningococcal-unknown type vaccine, calculated only among adolescents aged 17 years at time of interview. Does not include adolescents who received their first and only dose of MenACWY at or after age 16 years; HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV). HPV UTD includes those with ≥3 doses and those with 2 doses when the first HPV vaccine dose was initiated before age 15 years and at least 5 months minus 4 days elapsed between the first and second dose.† ACIP revised the recommended HPV vaccination schedule in late 2016. The recommendation changed from a 3-dose to 2-dose series with appropriate spacing between receipt of the first and second dose for immunocompetent adolescents initiating the series before the 15th birthday. Three doses are still recommended for adolescents initiating the series between the ages of 15 and 26 years. Because of the change in recommendation, the graph includes estimates for ≥3 doses HPV from 2011 to 2015 and the HPV UTD estimate from 2016 to 2018. The routine ACIP recommendation for HPV vaccination was made for females in 2006 and for males in 2011. Because HPV vaccination was not recommended for males until 2011, coverage for all adolescents was not measured before that year.§ NIS-Teen implemented a revised adequate provider data definition (APD) in 2014 and retrospectively applied the revised APD definition to 2013 data. Estimates using different APD definitions might not be directly comparable.¶ NIS-Teen moved from a dual landline and cell phone sampling frame to a single cell phone sample frame in 2018, and estimates using 2017 data were calculated two ways, using the dual frame and retrospectively using the single cell phone sampling frame.] VACCINATION COVERAGE BY SELECTED CHARACTERISTICS Coverage for all measures of HPV and MenACWY vaccination and ≥2 varicella vaccine doses among adolescents without a history of varicella disease were lower among adolescents living in non-MSA areas than in those living in MSA principal cities (Table 2). The largest differences were in HPV up-to-date status (15.4 percentage point difference) and ≥2-dose MenACWY coverage (19.7 percentage point difference). Coverage differences between adolescents living in MSA nonprincipal cities and MSA principal cities were observed for HPV vaccination measures (5.3 and 7.0 percentage point differences for receipt of ≥1 dose and being up-to-date, respectively) and ≥3 hepatitis B doses (1.7 percentage points). Compared with adolescents with private health insurance, those with Medicaid had higher HPV vaccination coverage (8.8 and 5.5 percentage points